261 related articles for article (PubMed ID: 18483104)
1. Radioiodine therapy and Graves' ophthalmopathy.
Sisson JC; Schipper MJ; Nelson CC; Freitas JE; Frueh BR
J Nucl Med; 2008 Jun; 49(6):923-30. PubMed ID: 18483104
[TBL] [Abstract][Full Text] [Related]
2. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy.
Bartalena L; Marcocci C; Bogazzi F; Manetti L; Tanda ML; Dell'Unto E; Bruno-Bossio G; Nardi M; Bartolomei MP; Lepri A; Rossi G; Martino E; Pinchera A
N Engl J Med; 1998 Jan; 338(2):73-8. PubMed ID: 9420337
[TBL] [Abstract][Full Text] [Related]
3. Clinical results of anti-inflammatory therapy in Graves' ophthalmopathy and association with thyroidal autoantibodies.
Eckstein AK; Plicht M; Lax H; Hirche H; Quadbeck B; Mann K; Steuhl KP; Esser J; Morgenthaler NG
Clin Endocrinol (Oxf); 2004 Nov; 61(5):612-8. PubMed ID: 15521965
[TBL] [Abstract][Full Text] [Related]
4. Graves' ophthalmopathy and 131I therapy.
Marcocci C; Bartalena L; Tanda ML; Manetti L; Dell'Unto E; Mazzi B; Rocchi R; Barbesino G; Pinchera A
Q J Nucl Med; 1999 Dec; 43(4):307-12. PubMed ID: 10731781
[TBL] [Abstract][Full Text] [Related]
5. Changes in graves' ophthalmopathy after radioiodine and anti-thyroid drug treatment of Graves' disease from 2 prospective, randomized, open-label, blinded end point studies.
Chen DY; Schneider PF; Zhang XS; Luo XY; He ZM; Chen TH
Exp Clin Endocrinol Diabetes; 2014 Jan; 122(1):1-6. PubMed ID: 24203649
[TBL] [Abstract][Full Text] [Related]
6. Use of corticosteroids to prevent progression of Graves' ophthalmopathy after radioiodine therapy for hyperthyroidism.
Bartalena L; Marcocci C; Bogazzi F; Panicucci M; Lepri A; Pinchera A
N Engl J Med; 1989 Nov; 321(20):1349-52. PubMed ID: 2811943
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Graves' hyperthyroidism--prognostic factors for outcome.
Alfadda A; Malabu UH; El-Desouki MI; Al-Rubeaan KA; Al-Ruhaily AD; Fouda MA; Al-Maatouq MA; Sulimani RA
Saudi Med J; 2007 Feb; 28(2):225-30. PubMed ID: 17268701
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of hyperthyroidism caused by Graves' disease or toxic multinodular goitre by radioiodine: over 80% cure retrospectively after one calculated dose].
Bakker SC; Zanin DE; Zweers EJ
Ned Tijdschr Geneeskd; 2002 Sep; 146(39):1837-41. PubMed ID: 12382370
[TBL] [Abstract][Full Text] [Related]
9. The influence of radioiodine therapy on ocular changes and their relation to urine cotinine level in patients with Graves' Ophthalmopathy.
Czarnywojtek A; Zgorzalewicz-Stachowiak M; Budny B; Wasko R; Florek E; Szczepanek E; Komar-Rychlicka K; Waligorska-Stachura J; Kurdybacha P; Miechowicz I; Ruchala M
Neuro Endocrinol Lett; 2013; 34(3):241-8. PubMed ID: 23685424
[TBL] [Abstract][Full Text] [Related]
10. Patients with severe Graves' ophthalmopathy have a higher risk of relapsing hyperthyroidism and are unlikely to remain in remission.
Eckstein AK; Lax H; Lösch C; Glowacka D; Plicht M; Mann K; Esser J; Morgenthaler NG
Clin Endocrinol (Oxf); 2007 Oct; 67(4):607-12. PubMed ID: 17880407
[TBL] [Abstract][Full Text] [Related]
11. Radioiodine treatment in autoimmune hyperthyroidism: analysis of outcomes in relation to dosage.
Hernández-Jiménez S; Pachón-Burgos A; Aguilar-Salinas CA; Andrade V; Reynoso R; Ríos A; Reza-Albarrán AA; Mehta R; González-Treviño O; Gómez-Pérez FJ; Pérez-Enríquezi B; Rull JA
Arch Med Res; 2007 Feb; 38(2):185-9. PubMed ID: 17227727
[TBL] [Abstract][Full Text] [Related]
12. The application of temperature measurement of the eyes by digital infrared thermal imaging as a prognostic factor of methylprednisolone pulse therapy for Graves' ophthalmopathy.
Shih SR; Li HY; Hsiao YL; Chang TC
Acta Ophthalmol; 2010 Aug; 88(5):e154-9. PubMed ID: 20553230
[TBL] [Abstract][Full Text] [Related]
13. Radioactive iodine therapy in Graves' hyperthyroidism.
Sankar R; Sripathy G
Natl Med J India; 2000; 13(5):246-51. PubMed ID: 11190053
[TBL] [Abstract][Full Text] [Related]
14. A prospective study of the effects of radioiodine therapy for hyperthyroidism in patients with minimally active graves' ophthalmopathy.
Perros P; Kendall-Taylor P; Neoh C; Frewin S; Dickinson J
J Clin Endocrinol Metab; 2005 Sep; 90(9):5321-3. PubMed ID: 15985483
[TBL] [Abstract][Full Text] [Related]
15. What influences early hypothyroidism after radioiodine treatment for Graves' hyperthyroidism?
Vijayakumar V; Ali S; Nishino T; Nusynowitz M
Clin Nucl Med; 2006 Nov; 31(11):688-9. PubMed ID: 17053385
[TBL] [Abstract][Full Text] [Related]
16. Management of Graves' ophthalmopathy.
Wiersinga WM
Nat Clin Pract Endocrinol Metab; 2007 May; 3(5):396-404. PubMed ID: 17452966
[TBL] [Abstract][Full Text] [Related]
17. Administration of additional inactive iodide during radioiodine therapy for Graves' disease: who might benefit?
Dietlein M; Moka D; Reinholz U; Schmidt M; Schomäcker K; Schicha H; Wellner U
Nuklearmedizin; 2007; 46(3):77-84. PubMed ID: 17549318
[TBL] [Abstract][Full Text] [Related]
18. [Radioiodine therapy of Graves' disease--quality assurance and radiation protection].
Reiners C
Z Arztl Fortbild Qualitatssich; 1999 Apr; 93 Suppl 1():61-6. PubMed ID: 10355053
[TBL] [Abstract][Full Text] [Related]
19. Thyroid cancer prevalence after radioiodine treatment of hyperthyroidism.
Angusti T; Codegone A; Pellerito R; Favero A
J Nucl Med; 2000 Jun; 41(6):1006-9. PubMed ID: 10855625
[TBL] [Abstract][Full Text] [Related]
20. Thyroid-associated ophthalmopathy after treatment for Graves' hyperthyroidism with antithyroid drugs or iodine-131.
Träisk F; Tallstedt L; Abraham-Nordling M; Andersson T; Berg G; Calissendorff J; Hallengren B; Hedner P; Lantz M; Nyström E; Ponjavic V; Taube A; Törring O; Wallin G; Asman P; Lundell G;
J Clin Endocrinol Metab; 2009 Oct; 94(10):3700-7. PubMed ID: 19723755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
